Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Janssen history
Janssen company history timeline
Based in Belgium, Janssen Pharmaceutica was established in 1953 by a young medical doctor, Dr Paul Janssen.
Janssen's work consisted of synthesizing molecules, and by 1954, Janssen had synthesized his fifth molecule--R5, better known as ambucetamide.
By 1955, Janssen had released the drug under the brand name Neomeritime.
In 1959, Janssen launched a new drug for the treatment of schizophrenia, called haloperidol.
In 1959, for example, Johnson & Johnson had acquired Switzerland's Cilag-Chemie and the United States' McNeil Laboratories.
His company, Janssen Pharmaceutica, joined the Johnson & Johnson family of companies in 1961.
1964 The company's name is changed to Janssen Pharmaceutica.
In 1980, the company entered the United States, establishing a sales network where previously it had marketed its products through other J&J subsidiaries or under third-party brands.
1980 The company launches the first technology transfer agreement in China.
1992 The United States branch opens a new 270-acre campus in Titusville, New Jersey.
Dr Paul passed away in 2003.
In 2003, the company expanded its Irish site with the launch of construction of a facility for the production of active pharmaceutical intermediates (APIs).
The Dr Paul Janssen Award for Biomedical research was set up in his honour in 2004.
2006 The company merges its primary care and hospital products operations with those of sister company Ortho-McNeil Pharmaceuticals, creating a new entity, Ortho-McNeil Inc.
© Janssen Pharmaceutica NV December 2020.
Available: https://fortune.com/worlds-most-admired-companies/2020/search/. Accessed: December 2020.
Rate Janssen's efforts to communicate its history to employees.
Janssen jobs
Do you work at Janssen?
Does Janssen communicate its history to new hires?
Janssen competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| CHADD | 1987 | $2.0M | 19 | - |
| Endo Pharmaceuticals Inc | 1997 | $2.6B | 385 | 152 |
| Boehringer Ingelheim | 1984 | $17.2B | 52,391 | 390 |
| Daiichi Sankyo | 2005 | $9.0B | 15,348 | 198 |
| PDI | 1987 | $22.0M | 350 | 69 |
| Warner Chilcott | 1968 | $105.1M | 3,000 | - |
| Merck | 1891 | $64.2B | 74,000 | 2,469 |
| Organon | - | $6.4B | 158 | 122 |
| UCB | 1928 | $5.7B | 7,600 | 89 |
| Bristol-Myers Squibb | 1887 | $48.3B | 30,000 | 836 |
Janssen history FAQs
Zippia gives an in-depth look into the details of Janssen, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Janssen. The employee data is based on information from people who have self-reported their past or current employments at Janssen. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Janssen. The data presented on this page does not represent the view of Janssen and its employees or that of Zippia.
Janssen may also be known as or be related to Janssen, Janssen Global Services LLC and Janssen Pharmaceuticals, Inc.